Dr. Marissa Joseph
Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)
Dr. Marissa Joseph graduated with a combined BSc (Honours) in Biochemistry and Biology from Dalhousie University, and then completed medical school at Dalhousie University. She is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.
Dr. Joseph is full time academic faculty at the University of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativa; genodermatoses, and equity, diversity and inclusivity.
Thursday NOV 24, 2022
Health Skin for Baby: The Role of Oat Emollients for all Skin Tones
- Understand the unique differences of infant skin vs. adult skin.
- Discuss the clinical manifestations of pediatric atopic dermatitis (AD) across skin types, and its impact on quality of life.
- Review the importance of skin directed therapy, highlighting the multifaceted benefits of colloidal oatmeal and the evidence supporting its use in Pediatric Atopic Dermatitis across skin types.
Thursday NOV 24, 2022
Exploring the Burden of Vitiligo: the Patient Perspective
- To understand the burden of vitiligo beyond skin
- To discuss factors that affect the level of disease burden in patients
Vitiligo is a chronic autoimmune disease characterized by the destruction of melanocytes, resulting in pale or white patches of skin. It is associated with significant quality-of-life impairment in routine activities, employment, and psychosocial health. This presentation will review the finding from a global, observational, cross-sectional analysis involving 3,541 people diagnosed with vitiligo (n=200 from Canada), with a focus on the patients’ quality life, mental health and treatment experience.